“Lucigen Corporation and Research Corporation Technologies (RCT) today announced a partnership to commercialize and distribute the CleanColi™ Expression System, the first Escherichia coli (E. coli)-based recombinant system that lacks unwanted endotoxin. Lucigen will produce and sell kits containing CleanColi™ competent cells and provide contract research services for the CleanColi™ Expression System. Lucigen simultaneously announces the release of a CleanColi™ competent cell line enabling the production of proteins virtually free of endotoxin contamination, thereby minimizing purification and allowing faster and more accurate screening of biological targets for drug discovery research. Under the partnership, RCT will be responsible for the CleanColi™ commercial licensing programs.”
About Lucigen Corporation
Located in Middleton, Wis., Lucigen delivers advanced molecular biology products and services to life scientists by inventing solutions to the most difficult problems in DNA cloning, amplification, protein expression, and next generation sequencing. With a focus on simplifying genomic research, Lucigen offers a wide selection of cloning kits, competent cells, and enzymes that enable scientists to quickly and easily complete even the most challenging molecular biology experiments.
Read more at Business Wire.